Centre for Evolution and Cancer (CEC)
@cec-icr.bsky.social
Evolution and cancer research @icrlondon.bsky.social.
Interests include:
drug resistance
pre-malignancy and early detection
epigenetics
plasticity
population genetics
microbiome
lineage tracing
biotech
Director @trevorgraham.bsky.social
Interests include:
drug resistance
pre-malignancy and early detection
epigenetics
plasticity
population genetics
microbiome
lineage tracing
biotech
Director @trevorgraham.bsky.social
Reposted by Centre for Evolution and Cancer (CEC)
Of course, the original idea of Adaptive Therapy was from the visionary Robert (Bob) Gatenby at @moffittnews.bsky.social. His seminal paper:
aacrjournals.org/cancerres/ar...
& lots of work since, with the epicentre being @sandyanderson.bsky.social's Centre at @moffittnews.bsky.social
aacrjournals.org/cancerres/ar...
& lots of work since, with the epicentre being @sandyanderson.bsky.social's Centre at @moffittnews.bsky.social
Adaptive Therapy
Abstract. A number of successful systemic therapies are available for treatment of disseminated cancers. However, tumor response is often transient, and therapy frequently fails due to emergence of re...
aacrjournals.org
May 2, 2025 at 12:58 PM
Of course, the original idea of Adaptive Therapy was from the visionary Robert (Bob) Gatenby at @moffittnews.bsky.social. His seminal paper:
aacrjournals.org/cancerres/ar...
& lots of work since, with the epicentre being @sandyanderson.bsky.social's Centre at @moffittnews.bsky.social
aacrjournals.org/cancerres/ar...
& lots of work since, with the epicentre being @sandyanderson.bsky.social's Centre at @moffittnews.bsky.social
Reposted by Centre for Evolution and Cancer (CEC)
In other words - remarkably - it could be that less drug, less often leads to better outcomes for some patients with ovarian cancer.
We eagerly await the clinical trial results - they will be definitive.
We eagerly await the clinical trial results - they will be definitive.
May 2, 2025 at 12:52 PM
In other words - remarkably - it could be that less drug, less often leads to better outcomes for some patients with ovarian cancer.
We eagerly await the clinical trial results - they will be definitive.
We eagerly await the clinical trial results - they will be definitive.
Reposted by Centre for Evolution and Cancer (CEC)
This means "adaptive therapy" where chemo dose is reduced when the tumour responds well could be a route to long-term tumour control for ovarian cancer (for certain disease types and stages). @mlockley.bsky.social is testing this in the ACTOv clinical trial: bmjopen.bmj.com/content/14/1...
Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on cha...
Introduction Adaptive ChemoTherapy for Ovarian cancer (ACTOv) is a phase II, multicentre, randomised controlled trial, evaluating an adaptive therapy (AT) regimen with carboplatin in women with relaps...
bmjopen.bmj.com
May 2, 2025 at 12:50 PM
This means "adaptive therapy" where chemo dose is reduced when the tumour responds well could be a route to long-term tumour control for ovarian cancer (for certain disease types and stages). @mlockley.bsky.social is testing this in the ACTOv clinical trial: bmjopen.bmj.com/content/14/1...